

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 47/48		A1	(11) International Publication Number: WO 92/02256 (43) International Publication Date: 20 February 1992 (20.02.92)
<p>(21) International Application Number: PCT/US91/05360 (22) International Filing Date: 29 July 1991 (29.07.91)</p> <p>(30) Priority data: 560,614 1 August 1990 (01.08.90) US</p> <p>(71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 300 Lakeside Drive, 22nd Floor, Oakland, CA 94612-3550 (US).</p> <p>(72) Inventors: YAKSH, Tony, L. ; 4219 St. James Place, San Diego, CA 92103 (US). HILL, Harlan, F. ; 8032 - 39th Avenue N.E., Seattle, WA 98115 (US).</p>		<p>(74) Agent: SHELTON, Dennis, K.; Christensen, O'Connor, Johnson & Kindness, 2800 Pacific First Centre, 1420 Fifth Avenue, Seattle, WA 98101 (US).</p> <p>(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI + patent), SU, TD (OAPI patent), TG (OAPI patent).</p> <p>Published <i>With international search report Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: CYCLODEXTRIN COMPLEXES FOR NEURAXIAL ADMINISTRATION OF DRUGS</p> <p>0.02% Cdex 20% Cdex 0.002% Cdex 2% Cdex SALINE</p> <p>AUC: HOT PLATE</p> <p>INTRATHECAL MORPHINE DOSE (μg)</p> <p>2% Cdex 0.02% Cdex 0.002% Cdex 20% Cdex SALINE</p> <p>AUC: HOT PLATE</p> <p>INTRATHECAL LOFENTANIL DOSE (μg)</p>			
<p>(57) Abstract</p> <p>A method of delivering a drug to a patient, comprising administering said drug to the neuraxis of said patient in the form of a complex between said drug and a cyclodextrin, the cyclodextrin comprising at least one substituent to reduce crystallization of the complex or the cyclodextrin. Compositions suitable for carrying out the method are also disclosed.</p>			

+ DESIGNATIONS OF "SU"

It is not yet known for which States of the former Soviet Union any designation of the Soviet Union has effect.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	RU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

**CYCLODEXTRIN COMPLEXES
FOR NEURAXIAL ADMINISTRATION OF DRUGS**

Technical Field

This invention relates to compositions and methods for administering drugs
5 to the neuraxis of a patient.

Background of the Invention

From a therapeutic standpoint, a large number of drugs are employed for
their central nervous system action. Examples of such classes of agents are
centrally acting analgesics, antineoplastic agents, cerebral ischemia protectants,
10 and compensatory therapeutic agents for central disorders such as Alzheimer's or
schizophrenia. Other examples include drugs targeted to a variety of central
nervous system disorders.

The spinal (intrathecal/epidural) administration of the centrally acting drugs
described above has been shown to have considerable therapeutic efficacy for the
15 treatment of several clinical states including pain, spasticity, central nervous
system tumors and infections. In particular, the epidural administration of opioid
analgesics represents an important clinical tool for the management of acute and
chronic pain states Yaksh, T.L., Noueihed, R.Y., Durant, P.A. : *Anesthesiology*
64:54-66 (1986). The drug most commonly employed is morphine. Its kinetics are
20 characterized by slow onset and a prolonged residency time in cerebrospinal fluid
(CSF) Payne, R.: *Acta Anaesthesiol. Scand.* (31, suppl.) 85:38 46 (1987).
Sufentanil and other anilinopiperidines may be important alternatives to morphine
by this route. These are powerful mu opioid receptor agonists that appear to have
a higher intrinsic efficacy than morphine Stevens, C.W., Yaksh T.L.: *J.
25 Pharmacol. Exp. Ther.* 250:1-8 (1989) and have higher lipid partition coefficients,
indicating that these drugs will have a rapid onset.

Unfortunately, neuraxial administration of centrally acting drugs has some
drawbacks. Most problematic is the fact that these drugs also achieve significant

-2-

plasma concentrations after their administration. For example, epidurally administered drugs have several routes for redistribution: (a) movement into fat; (b) passage through the dura and thence into the spinal cord; and (c) most importantly, movement into the thin-walled epidural venous plexus and thence 5 into the systemic circulation Yaksh, T.L.: *Pain* 11:293-346 (1981). Thus, following spinal administration of sufentanil or alfentanil, there are prominent blood concentrations of opioids early on which correspond with the rapid egress of drug from the epidural space Sabbe M.B., Yaksh T.L.: *J. Pain and Symp. Manag.* in press (1990). This vascular redistribution clearly results in powerful and acute 10 supraspinal side effects. Such side effects are often serious and sometimes fatal.

A key goal of the present invention has been to develop improved methods that will allow the routine, acute and chronic administration of agents into the neuraxis via intraventricular, epidural, intrathecal, intracisternal and related routes (hereafter jointly referred to as neuraxial routes) without the redistribution 15 problem detailed above. An ideal therapeutic modality requires: (a) the prolonged and predictable presence of therapeutic concentrations of neuraxially-administered drugs at or near their sites of action in spinal cord or brain; (b) the limitation of drug distribution to the desired site of action within the CNS (i.e., minimization of its movement into the vasculature); and (c) the availability of a 20 vehicle which permits the delivery of large concentrations of drugs in relatively small volumes. Typically, administration of drugs by the neuraxial routes may be limited by their relative solubility in water or lipids and/or factors that govern their kinetics and make them less than fully effective. Thus, agents with high lipid partition coefficients may require unusual vehicles that are not routinely 25 biocompatible. Similarly, such lipophilic agents may be cleared very rapidly after neuraxial administration, giving them a short residence time in spinal or brain tissue and leading to unacceptably high peripheral plasma or tissue concentrations. These characteristics may lead to the failure of a particular drug or significantly limit its utility. The development of a vehicle that can alter the 30 rate at which agents may undergo redistribution, render the agent soluble, maintain its bioavailability, and be compatible with the neuraxis of a patient would be of particular significance.

The inventors are the first to recognize that the problems associated with neuraxial administration of drugs may be ameliorated by administering a drug or 35 drugs to the neuraxis of a patient in the form of a complex between the drug and a cyclodextrin. Cyclodextrin complexes with other types of drugs, and/or for other routes of administration have previously been known. For example, U.S.

5 Patent 4,869,904 is directed to a sustained release drug preparation made up of an inclusion complex between a drug and a cyclodextrin derivative. Neuraxial administration of these prior complexes was not reported. In contrast to this prior work, the present applicants have discovered that complexes between cyclodextrins and drugs, when administered to the neuraxis of a patient, can, *inter alia*, reduce or retard diffusion or passage of the drug into the vasculature of a patient and, in some cases, increase the effectiveness of the drug *in vivo*.

10 Pitha, J., et al. *Life Sciences* 43:493-502 (1988), discusses the use of cyclodextrin derivatives to dissolve drugs. In one portion of this paper, it discloses intracerebral injection of a cyclodextrin derivative complexed with alkylating pindolol. In contrast to the present invention, alkylating pindolol is not a therapeutic drug, so its complex with the derivatized cyclodextrin is not a drug:cyclodextrin complex as used herein. More importantly, this prior reference does not disclose any advantages of administering a drug:cyclodextrin complex to 15 the neuraxis of a patient.

20 Another prior publication of interest, Kawasaki, A. et al. *Pharmacokinetics* 8:61-63 (1974), discusses pharmacological studies on β -cyclodextrin clathrate compounds with prostaglandin E₂. In this work, the prostaglandin molecule was administered to animals by a variety of routes, including oral, intravenous and intracisternal. However, these authors concluded 25 that β -cyclodextrin showed no effect in their system. It is important to note that the cyclodextrins used to form drug complexes for the purposes herein must be derivatized relative to the parent cyclodextrin as will be discussed further herein. The cyclodextrin molecule used in this prior publication was unsubstituted.

Applicants are not aware of any prior reports of administration of complexes between drugs and substituted cyclodextrins to the neuraxis of a patient, as disclosed in greater detail herein below.

Summary of the Invention

30 The present inventors have discovered that administration of complexes between drugs and substituted cyclodextrins to the neuraxis of a patient provides superior results as compared to administration of the drug alone. The cyclodextrins of the present invention have hydrophilic exteriors and relatively hydrophobic interiors and are capable of forming complexes with a variety of 35 neuraxially-active drugs. Administration by this means represents an important way to prevent free clearance of the drug from the central nervous system or epidural space into the vasculature of the patient and may facilitate diffusion of

the drug into the spinal cord or brain, thus increasing its availability at specific receptor sites in the central nervous system after administration.

Brief Description of the Drawings

FIGURE 1 shows the area under the time effect curve (AUC) measured on the hot plate (52.5°C) versus the intrathecal dose of lofentanil (bottom panel) and morphine (top panel) administered in saline or in the presence of several concentrations of a cyclodextrin. Each point presents the mean of four to eight animals. Note that the Y-axis of the lofentanil and morphine curves are different. Standard error indicators are deleted for clarity. By one way ANOVA and subsequent Newman Keuls statistical tests, the effects observed at the highest dose of of lofentanil are ordered ($p < 0.05$): 2%, 0.02%, 20%, 0.002%, saline; for morphine, the ordering at the 10 microgram dose is: 0.02%, 20%, 0.002%, 2%, saline.

FIGURE 2 shows the respiratory depressant effects of epidural treatments as percent decrease in the minute ventilation CO_2 function (top row); percent change in the threshold for thermal pain (middle row) and the lumbar and cisternal cerebrospinal fluid (CSF) concentrations of drug (bottom row) in a dog in which the first injection was of alfentanil (400 micrograms) in saline (left column) and the second injection (given seven days later) was of alfentanil (400 micrograms) in 20% cyclodextrin (right column).

FIGURE 3 shows the meningeal dural permeability of cyclodextrin-incorporated sufentanil (left panel) or alfentanil (right panel) as a function of time. Each data point represents the accumulated amount (mass) of alfentanil or sufentanil that diffused through samples of total meninges (dura plus arachnoid plus pia mater from monkey spinal cord) over time. Line slopes represent meningeal flux. Solid circles are data for alfentanil or sufentanil dissolved in artificial CSF, open circles are results with alfentanil or sufentanil in 20% CDEX. The result using meninges isolated from monkey spinal cord indicates that cyclodextrin complex formation with opioids may be useful for controlling availability of analgesic drugs for meningeal transfer.

Detailed Description of the Preferred Embodiments

In accordance with the present invention, it has now been recognized that many of the problems associated with neuraxial administration of drugs to patients can be solved or minimized by administering the drugs in the form of complexes with cyclodextrins. For the purposes of the present invention, unsubstituted cyclodextrins, that is, those that have not been modified with substituents, are not desirable, at least in part because it is more likely that they will crystallize or otherwise precipitate out of solution *in vivo*.

Generally speaking, cyclodextrins are cyclic compounds having a cylindrical molecular structure wherein the inner surface and the outer surface are different in their hydrophilic or lipophilic nature, thus permitting other molecules, known as "guest molecules," of suitable dimensions, or parts thereof, to penetrate into the 5 intramolecular cavity of the inner part of the cylindrical cyclodextrin "host molecule," thereby forming an inclusion complex. In some instances, the drug may form a complex with the cyclodextrin at a site different from the intramolecular cavity of the cyclodextrin. Both types of complexes are contemplated to form part of the present invention. For the majority of drug: cyclodextrin 10 combinations, the inclusion complex will be the predominant or sole complex formed; thus, inclusion complexes are generally preferred for the purposes disclosed herein.

To be useful in connection with the present invention, a cyclodextrin molecule must be capable of forming a complex with a drug of interest and both 15 the cyclodextrin and the inclusion complex must be compatible with neuraxial administration. In structural terms, the cyclodextrin that may be used in connection with the present invention will be composed of saccharide moieties linked so as to form a cylindrical structure, having an intramolecular binding cavity. The saccharide moieties may be any of those that can be coupled together 20 either directly or through molecular linkers to form structures that are capable of binding to a drug for neuraxial administration. The well-known "natural" cyclodextrins are composed of D-glucopyranose bound together by 1, 4 linkages. Any of these compounds are useful for the purposes of the present invention, when 25 derivatized as discussed further below. Typically, these preferred compounds will be made up of six, seven or eight molecules of D-glucopyranose. These cyclodextrins are referred to in the art as alpha, beta, and gamma cyclodextrins, respectively.

It is well known that some types of cyclodextrins are capable of crystallizing 30 in vivo, thereby interfering with normal processes, and may lead to renal damage or failure. See, for example, Pitha, J. et al. *Life Sciences*, 43:493-502 (1988); Pitha, J., et al. *International Journal of Pharmaceutics*, 29:73-82 (1986); and Pitha, J. *Neurotransmissions*, 5:1-4 (1989), each of which is hereby incorporated by reference. Cyclodextrin molecules that readily crystallize or precipitate from solution in vivo are not useful for the present purposes. To prevent this problem, 35 the cyclodextrins of the present invention must be derivatized as compared to the parent cyclodextrin molecules. Thus, for example, with respect to alpha, beta, and gamma cyclodextrins, these parent molecules must be modified with

substituents in a manner that interferes with or prevents their crystallization or precipitation from solution, especially under *in vivo* conditions.

The degree and manner of derivatization of the cyclodextrin is not specifically limited except that it must be sufficient to minimize the problems set forth above. The substituents are preferably hydrophilic so as to render the cyclodextrin more water soluble. Additionally, the cyclodextrin is preferably nonsymmetrically and incompletely substituted, which reduces its crystallizability. The substituents in accordance with the present invention are preferably selected from $-\text{OCH}_3$, $-\text{ROH}$, $-\text{R(OH)}_2$, $-\text{RSO}_3\text{H}$, $-\text{CO}_2\text{R}$, $-\text{NHR}$, $-\text{NR}_2$, $-\text{NROH}$, and $-\text{SiR}_3$, wherein each R is independently selected from C_{1-10} alkyl groups that may be linear, branched, or cyclic. Particularly preferred substituents are $-\text{OCH}_3$ and $-\text{ROH}$. Where possible, pharmaceutically acceptable salts of the above groups are also encompassed by the present invention.

Each of the saccharide rings in the cyclodextrin may be substituted at the 2, 15 3, and 6 positions on the ring. In accordance with the present invention, any one of these sites or a combination of sites (e.g., 2 and 3; 2 and 6, 3 and 6, or 2 and 3 and 6) may be substituted with one or more of the substituents described herein. For example, in a preferred embodiment, the cyclodextrin molecule will be substituted asymmetrically with α -hydroxypropyl groups at some but not all the 20 2 positions. The most preferred cyclodextrin is α -cyclodextrin (having 7 glucose moieties) substituted (i.e., derivatized) with hydroxypropyl groups. A particularly preferred cyclodextrin is 2-hydroxypropyl- β -cyclodextrin (also referred to herein as CDEX).

Additional specific examples of substituents that may be attached to the 25 saccharide molecules of the cyclodextrins are: hydroxyethyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, butylsulfonate, propylacetate, ethylamine, ethylene glycol, and the like.

In addition to pure substituted cyclodextrins, it is also possible in accordance 30 with the present invention to utilize mixtures of cyclodextrins. In one specific example of such a mixture, a parent cyclodextrin (e.g., β -cyclodextrin) is derivatized asymmetrically to less than 100% so that the final composition contains both the parent cyclodextrin and a mixture of cyclodextrins substituted to differing degrees by hydroxypropyl groups. In this situation, it is useful to refer to an average degree of substitution of the overall mixture of cyclodextrins and to 35 define the parent cyclodextrin as being zero percent substituted and the composition in which each cyclodextrin molecule is substituted at all molecular positions as being 100% substituted. For the purposes herein, the preferred degree

of substitution ranges from 10% to 100%, with the more preferred range being from 15% to 80%. Lower or higher degrees of substitution may be required for particular drugs or for particular types of desired effects *in vivo*.

It is preferred, although not believed to be essential in all cases, that the drug be able to dissociate from the cyclodextrin complex *in vivo* so that the free drug is available for its intended pharmacological activity. Theoretical considerations suggest that the rate of dissociation is proportional to several variables, including: (a) the stability constant of the drug-cyclodextrin complex; (b) the relative amounts (e.g., molar ratio) of drug and cyclodextrin; and (c) the local concentration of cyclodextrin in the volume into which the complex is delivered. If there is a molar excess of cyclodextrin, the likelihood of finding free drug in solution or in the neuraxial space is proportionately diminished. In the case of the traditional routes of administration (e.g., intravenous or oral), the total volume of drug or the microencapsulated complex administered is diluted in a large, essentially infinite space or volume. Thus, the quantity of cyclodextrin employed may not be critical as long as it is sufficient to bind a significant proportion of the available drug and the rate of dissolution of the inclusion complex will be largely dependent on the stability of the complex. On the other hand, if the cyclodextrin drug complex is administered into a space or volume from which the drug, but not the cyclodextrin, may readily diffuse, then molar excesses of cyclodextrin will reduce proportionately the rate at which the drug molecule will be free to diffuse, i.e., free molecules will be in equilibrium with the excess binding sites provided by cyclodextrin. Based on this consideration, agents such as cyclodextrin injected into the epidural, intrathecal, or intraventricular spaces (as cyclodextrin-drug complexes) can have optimal concentrations or molar ratios of cyclodextrin to drug for drug delivery, depending upon the rate at which the appearance of free drug is desired.

The freedom with which a complexed drug may exit the environment of the cyclodextrin cavity is a function of the size of the drug molecule, its shape, and its lipid solubility. Lipophilic drug molecules bind with greater affinity to the hydrophobic interior of the cyclodextrin. If the lipid solubility of the drug is too high, the drug may not dissociate at all, even when the complex approaches a lipid membrane; thus, some drugs would be rendered inactive since they would not reach specific receptors in tissue in an active form. In its simplest form, the interaction between a drug and a cyclodextrin resembles that of a competitive ligand, and as such obeys the law of mass action with affinity proportional to the lipid solubility and other physicochemical properties of the drug. Pitha, J.:

Neurotransmissions Research Biochemicals, Inc., Massachusetts 5 (1989).

It is notable that increasing the degree of substitution on the cyclodextrin will increase the apparent binding affinity of lipophilic drugs for the cyclodextrin molecule. For opioids with high lipid solubility, it is expected that increased 5 substitution will favor controlled release. However, for opioids with low to intermediate lipid solubility, a lower degree of substitution may be more favorable.

For purposes of the present invention, it is a relatively straightforward matter to determine whether a given cyclodextrin and drug combination is likely 10 to be *in vivo* dissociable. It is well known that one may measure the affinity constant between a drug and a ligand by way of standard techniques. For example, the interaction between a cyclodextrin and a drug can be studied by equilibrium dialysis, or other suitable techniques. The equilibrium binding data can be analyzed by a standard Scatchard plot, which readily allows one to 15 calculate the intrinsic ligand dissociation constant. Once a dissociation constant is known for a particular drug/cyclodextrin combination, a reasonable estimate can be made as to whether the complex will be dissociable *in vivo*. If the measured dissociation constant is higher than, for example, 10^{-6} M *in vivo* dissociation may be expected not to occur to any significant degree or to occur at 20 very slow rate. The conditions under which the binding constant are measured may be rendered more similar to *in vivo* conditions by adjustment, for example, of pH and the concentrations of various ions, etc. Binding constants measured under these conditions may more closely approximate the binding constant under *in vivo* 25 conditions.

It should be stressed that a slow rate of dissociation does not in theory 30 exclude the utility of the cyclodextrin-drug complex. First, the dissociation is based on the law of mass action and if the drug is diffusing into a large volume, such as the CSF or the spinal cord, then the equilibrium conditions will permit the development of sustained steady state concentrations. Thus, the ability to define the dissociation constant can be used to predict *a priori* whether the drug complex 35 will reach a high or low steady state concentration relative to the amount of drug administered. It would be possible, therefore, with this information to tailor the drug delivery profile. Agents with slow rates of dissociation would be given in larger amounts to achieve the given level of free drug in the appropriate biospace.

A second theoretical consideration mentioned above involves the relative concentrations of drug and cyclodextrin when given into a kinetically limited space. If the drug: cyclodextrin ratio is low and there is a large amount of

cyclodextrin, then the concentration of free drug will be correspondingly diminished. In other words, the presence of excesses of unbound cyclodextrin will represent a reservoir of binding sites which will compete with the tissue for drug redistribution. It should be noted that this is fundamentally different from a 5 systemic route of administration where the total cyclodextrin (bound and free) is distributed into an essentially infinite volume (the body vasculature tree) in contrast to the limited volume of the cerebrospinal fluid or epidural space. If too much cyclodextrin is administered with the drug, the drug activity will be diminished; if too little, then the redistribution of the drug into the vasculature 10 will not be sufficiently delayed. Thus, there are three factors that particularly govern the neuraxial redistribution of the drug-cyclodextrin complex: the dissociation constant of the drug cyclodextrin complex, the drug/cyclodextrin ratio, and the total dose of cyclodextrin administered into the particular space. It can be seen that these variables will result in an optimal drug dose/cyclodextrin 15 ratio and an important consideration is the ability to define these ratios with *in vitro/in vivo* models.

It is also contemplated in connection with this invention that some drug:cyclodextrin complexes will be pharmacologically active even though the drug has not dissociated from the complex. This could occur, for example, if the 20 active portion of the drug were available for interaction at the target site (e.g., a specific receptor) even while the drug molecule was complexed by the cyclodextrin. Another possibility is that the drug could form a complex with a site on the cyclodextrin molecule other than the intramolecular cavity, i.e., on the 25 surface of the cyclodextrin (i.e., drug binding to substituent groups, such as hydroxypropyl side chains). Such complexes also form part of the present invention.

In general, the molar ratio of drug to cyclodextrin can vary over a relatively wide range. The precise range will depend upon the mode of administration and the particular drug and cyclodextrins employed. For epidural administration, the 30 molar ratio will generally range from about 1:10 to 1:10,000; for intrathecal and intraventricular administration, the molar ratio will generally range from about 1:10 to about 1:1,000. These ranges are given to exemplify typical ranges; they will not necessarily apply to every drug:cyclodextrin complex with useful neuraxial activity.

35 In order to ascertain whether a given inclusion complex has *in vivo* activity, standard tests in *in vivo* models, such as those exemplified below, may be employed. Such tests will also readily provide information on whether there is a

-10-

shift in the activity/time curve for a given complex. *In vitro* determination of binding constants between the drug and the cyclodextrin and *ex vivo* measurements of meningeal flux coupled with results in *in vivo* models therefore enable one to determine whether a given complex is active *in vivo*.

5 In the development of the use of cyclodextrins as a neuraxial delivery system, the inventors have employed several *in vivo* models in which the animal is chronically prepared with spinal intrathecal and/or spinal epidural catheters which allow nontraumatic injection of different drug agents in different vehicles. Using these models, the inventors were able to quantitatively define the effects and 10 distribution characteristics of agents given by the several routes and to concurrently assess potential local toxicity and drug redistribution kinetics. Pharmacologically and toxicologically, these systems are highly predictive of effects in human patients.

15 In some of these preliminary studies, the inventors have observed that there were modest increases in the antinociceptive effects for morphine, but a highly significant increase in the duration of action for lofentanil after intrathecal administration in a cyclodextrin, as compared to a saline vehicle. No evidence of toxicity was observed in these preliminary studies.

20 In addition to the *in vivo* studies showing safety, efficacy, and further characterizing the role of the composition of the drug:cyclodextrin combinations on kinetics and drug activity, the inventors have also examined the influence of cyclodextrins on the rates of diffusion of particular model drugs, the opioid alkaloids, through live (*ex vivo*) samples of spinal cord dura matter, arachnoid matter and pia matter. These studies, reported in the examples below, can 25 determine the extent to which various concentrations of cyclodextrin can regulate and thereby prolong the duration of, for example, spinal action of epidurally or intrathecally administered complexes of cyclodextrin. Thus, these models serve as *ex vivo* systems that permit the rapid approximation of the optimal cyclodextrin:drug ratio required for the use of the complexation procedure for 30 other spinally administered agents, such as other opioids, and antineoplastic agents such as methotrexate and busulfan. Different components of the *ex vivo* meningeal permeability model are useful for predicting rates of diffusion of cyclodextrin complexes from the epidural space to the spinal cord (using the total meningeal complex to measure flux). This *ex vivo* research allows one to make 35 useful predictions as to what concentration of the cyclodextrin (and ratios of cyclodextrin to drug) will provide optimal drug:cyclodextrin combinations for yielding prolonged residency time after intrathecal/epidural administration.

The drugs that are useful for purposes of the present invention are not specifically limited, other than that they must be capable of forming a complex with a cyclodextrin and they must be suitable for administration to the neuraxis of a patient. By "neuraxis," as used herein, is meant any surface, region or volume of tissues that comprise the spinal cord, brain, or central nervous system. This would include, for example, the brain within the cranial cavity (intraventricular), the spinal canal (epidural), and the space between the dura-arachnoid mater and the pia mater (intrathecal). From a therapeutic standpoint, a large number of drugs are employed for such action. Typical of such classes of agents are centrally acting analgesics, antineoplastic agents, cerebral ischemia protectants, compensatory therapeutic agents for central disorders such as Alzheimer's or schizophrenia, and other drugs targeted to a variety of central nervous system disorders. Cancer chemotherapeutic agents such as methotrexate and busulfan are often employed in cases of central nervous system tumor involvement.

Methotrexate is commonly used intrathecally to obtain high neuraxial concentration. Occasionally, neuraxial agents are employed to reduce the likelihood of cerebrospinal fluid seeding as in meningeal carcinomatosis. See Kooistra, K.L. et al., *Cancer* 46:317-323 (1986). Combinations of methotrexate and a cyclodextrin could alter favorably the redistribution kinetics after intrathecal or neuraxial administration. Busulfan, a highly lipophilic agent, is useful for neuraxial tumor reduction, but when administered orally, it causes severe bone marrow depression, similar to several other cancer chemotherapeutic agents. Combinations of busulfan with cyclodextrin may allow its effective neuraxial use. Similar advantages may be achieved for a variety of drugs used for nonmetastatic syndromes in which neuraxial concentrations of drug have been proven effective. Examples of these cases include neuraxial fungal and meningeal infections. Delivery of local anesthetics could also be carried out in this manner. Other conditions that may be treated are: spasticity, seizure disorders, and arachnoiditis.

It is probable that in the near future, therapeutic agents for AIDS and other virally mediated conditions may be approached in this manner by drugs which have unfavorable or poor pharmacokinetic properties. Agents such as cyclodextrin could be of considerable advantage in these instances, not just because they provide very useful, nontoxic solubilizing means, but because of their effects on drug bioavailability.

Other drugs that have formed the basis for several preliminary tests conducted by the inventors are the opioid analgesics suitable for central

administration. Examples of such drugs are the following: alfentanil, sufentanil, lofentanil, fentanyl, and morphine.

The complexing methods according to this invention may be carried out by any of a number of standard methods known to those of ordinary skill in this art.

5 The precise physical method of forming the complex is relatively unimportant for the present invention as long as the complex is formed by the time that it is present in the neuraxis of the patient. Specific methods that may be used are: the kneading method, solution method, lyophilizing method, or the like.

A preferred method of producing the complexes for administration to a patient involves providing an aqueous solution that contains an appropriate amount of a drug to be complexed and a cyclodextrin and allowing the well-mixed solution to stand for a suitable period of time (e.g., from about $\frac{1}{2}$ hour to about 24 hours or more) to thereby allow a complex to form. The aqueous solution that is utilized to form the complex will generally be the same solution that is used to administer the complex. The drug:cyclodextrin complexes will preferably be administered to a patient in a physiologically acceptable medium, such as physiological saline containing standard additives for neuraxial administration of drugs. Preferred media are: dextrose (e.g., 1-5%) in sterile water or sterile water alone.

Confirmation of the formation of a complex of the drug with the cyclodextrin derivative may be confirmed by a variety of methods, including powder X-ray diffraction, dissolution behavior, scanning electron microscope analysis, differential thermal analysis, and infrared absorption.

The drug:cyclodextrin complexes described above may be administered to patients by standard procedures normally employed for administration of the uncomplexed drugs. The goal of such administration is to provide an effective amount of active drug to the neuraxis of a patient. As a first approximation, it is generally suitable to employ the standard dosages of the uncomplexed drugs to evaluate results with a given drug:cyclodextrin complex. However, in some instances, the activity of the drug will be enhanced (e.g., increased potency, increased efficacy, and/or increased duration) by administration as a complex with a cyclodextrin due, for example, to greater residence time of the active drug in its primary location of action and less supraspinal vascular or bulk flow redistribution. As a result, smaller doses of the complexed drug as compared to the uncomplexed drug may be found to be suitable for administration to a patient. The optimal dosage range may be determined by using standard animal models and/or actual clinical testing.

In general, the amount of the complex to be administered should be sufficient to effectively treat the condition being treated by a physician. Such conditions can include pain caused by a variety of disease states and/or injury, including cancer, pain caused by other stimuli (e.g., labor pain, post-surgical pain), 5 spasticity, CNS tumors and infections, and a variety of other disease states targeted by the drugs summarized above. One of ordinary skill will be able to determine appropriate effective amounts using the standard models disclosed herein and/or standard pharmacologic testing techniques.

Exemplary modes of administration of the above-described drugs include 10 epidural (administration into the peridural space); intrathecal (administration into the cerebrospinal fluid-containing space); intracranial (administration into the brain parenchyma); or intraventricular (administration into the cerebral ventricles).

Human patients are preferred; however, animal patients are also possible. 15 Thus, veterinary uses are also contemplated for purposes of the present invention.

In addition to methods of administration of drugs, the present invention also covers compositions suitable for such administration, which comprise a drug complexed by a substituted cyclodextrin and standard media for neuraxial administration of a given drug. This could include standard surfactants or other 20 drugs that do not form complexes but that interact physiologically or pharmacologically with the complexed drug (e.g., cyclodextrin: opioid with an α_2 -agonist such as dexmedetomidine).

The following examples are presented to illustrate the advantages of the present invention and to assist one of ordinary skill in making and using the 25 same. These examples are not intended in any way to otherwise limit the scope of the disclosure or the protection granted by Letters Patent hereon.

-14-

Examples

1. Drug Preparation

The 2 hydroxypropyl- β -cyclodextrin (CDEX: 40% substituted) was purchased from Research Biochemical Inc., Natick, MA. Other agents were obtained from the following sources: morphine sulfate (Merck); sufentanil citrate; alfentanil, HCl; and lofentanil oxalate (Janssen Pharmaceutica, also known as Janssen Research Foundation).

All drugs were prepared when indicated, either in sterile saline or in cyclodextrin dissolved in distilled water at the indicated percentage. In these conditions, the weighed drug was dissolved by simple mixing and agitation. Capsaicin was also administered dissolved in dimethylsulfoxide (DMSO: reagent grade, Sigma Chemical) and then brought to final volume in saline. In the meningeal permeability studies, drugs with or without cyclodextrin were dissolved in artificial cerebrospinal fluid.

15 2. Toxicity Studies

a. Lumbar intrathecal injections - rats: Rats (250-350 gm) were prepared with chronic intrathecal catheters placed in the lumbar intrathecal space. They received intrathecal administration of 15 μ l of 25% CDEX. There was no change either acutely or after 7 days in the motor function of these animals as assessed by the placing/stepping reflexes or bladder function (absence of urine stains on the abdomen). At 7 days, the levels of neuropeptides substance P and calcitonin gene-related peptide (CGRP) were measured after extraction of tissue, using radioimmunoassays. Tissue concentrations of these peptides, found in unmyelinated sensory afferent neurons, were unchanged when CDEX was administered in the absence of other agents. In contrast, the use of the vehicle dimethyl sulfoxide (25% in saline) resulted in a significant reduction in the levels of the two peptides.

b. Lumbar intrathecal injections - guinea pigs: Guinea pigs (male: 300-400 gm; N=12) were administered 20% CDEX by percutaneous puncture of the lumbar intrathecal space with a 30 gauge needle. There were no acute behavioral signs of agitation, indicating no irritation. There were no changes in the motor function of the animals as measured by placing, stepping and righting reflexes or ambulatory tests. No evidence of urine staining was noted.

c. Lumbar epidural injections - dogs: Beagle dogs (11-15 kg) prepared with lumbar epidural catheters received injections of 20% CDEX (2 ml; a standard volume of injection in this model). This treatment had no effect on the heart rate, bladder function or skin twitch response for periods of up to 7 days

-15-

after each acute injection. These data indicate the lack of toxicity of spinal CDEX.

5 d. Intraventricular injections - rats: In rats prepared with chronic intracerebral ventricular (ICVT) cannulae and electroencephalographic electrodes, the ICVT injection of CDEX (20%; in a standard volume of 10 μ l) had no effect upon general motor behavior, or EEG activity for periods of up to 7 days after injection.

3. Antinociceptive Activity

10 a. Intrathecal injection - rats: effects of a fixed CDEX concentration on drug action. Rats prepared with lumbar intrathecal catheters received injection of different amounts of morphine, sufentanil, alfentanil or lofentanil. Injections were made in volumes of 10 μ l of saline vehicle or in vehicle of 20% CDEX. For all drugs, there was a rightward shift in the intrathecal dose response curve (indicating increased potency) and an increase in the duration of 15 antinociceptive effect. As shown in Table 1, the ordering of the magnitude of increase in the potency (i.e., decrease in ED₅₀) at this concentration of CDEX was: alfentanil; lofentanil; morphine; and sufentanil. Also indicated is that with the addition of CDEX, there was a significant increase in the area under the analgesia time course curve (indicating increased duration of action) for each of 20 these four drugs.

Table 1

Effect of intrathecal 2-hydroxypropyl- β -cyclodextrin (20%) on the peak (MPE) and duration (AUC) of the antinociceptive effects in the rat of opioids given intrathecally on the hot plate test.

Spinal Drug	ED ₅₀ (μ g) (1)		AUC-3000 (μ g) (2)	
	Saline	CDEX	Saline	CDEX
Morphine	4.0	1.1	1.7	0.5
Alfentanil	8.2	1.0	80.	17.
Sufentanil	0.2	0.06	0.5	0.2
Lofentanil	0.1	0.02	0.04	0.015

1) MPE: % of the maximum possible effect upon the hot plate test; 2) AUC; area under the time effect curve calculated using the MPE x Time curve. The value given indicates the dose (μ g) required to produce an arbitrary AUC value of 3000; Each ED₅₀ (μ g) value (dose required to produce the maximum possible effect in 50% of the animals) presents the means of 12-18 rats. All differences between saline and CDEX groups are statistically significant by unpaired t-test at the p<0.05 level.

b. Intrathecal injections in rats: effects of altering CDEX concentration on the spinal effects of opioids. Rats prepared as above received injection of morphine (3 μ g/10 μ l) or lofentanil (0.1 μ g/10 μ l) dissolved in sterile saline, concentrations which produced small but measurable analgesic effects.

5 Other rats prepared as above received injections of these doses in concentration of CDEX of 20%, 2%, 0.2%, or 0.02%. As shown in Table 2, the optimal concentration yielding the most significant augmentation of antinociceptive (analgesic) effect in the hot plate test was 0.2% for morphine and 2% for 10 lofentanil. Concentrations on either side of 0.2% for morphine and 2% for lofentanil yielded progressively lesser effects. FIGURE 1 presents this data.

Table 2

15 **Effects of varying cyclodextrin concentrations on the area under the time-effect curves of intrathecal lofentanil (0.1 μ g/10 μ l) or morphine (3 μ g/10 μ l) in rats.**

		Cyclodextrin concentration (% w/v)					
	<u>Vehicle:</u>	saline	0.002	0.02	0.2	2.0	20.0
	<u>Intrathecal drug</u>						
20	Morphine (3 μ g)	46 (0.1)	55 (0.5)	112 (0.5)	30 (0.9)	23 (0.8)	33 (0.5)
	Lofentanil (0.1 μ g)	0.7 (0.2)	18 (0.2)	38 (1.4)	49 (1.2)	68 (1.7)	23 (0.5)

25 Values present the mean (SE) of the AUC /100 produced by the indicated dose of the opioid in the associated concentration of CDEX up to 20% or saline.

c. Effects of CDEX on the antinociceptive effects of epidural alfentanil in dogs. Dogs were prepared with lumbar epidural catheters and chronic tracheostomies. Respiratory function curves (slope of minute ventilation (Ve) vs. endtidal CO_2) were measured by using the Read rebreathing technique over an endtidal CO_2 range of 35 to 80 mmHg CO_2 . The skin twitch response to a thermal stimulus was used to assess the nociceptive threshold. Alfentanil (400 μ g) epidurally administered in saline normally yields a short lasting (<90 min) complete block of the nociceptive endpoint (skin twitch response) and a significant respiratory depression (reduced slope of Ve vs. CO_2), as indicated in Table 3. The injection of alfentanil with 20% CDEX resulted in neither analgesia nor changes in

-17-

respiratory function. The injection of the same dose of alfentanil in 2% CDEX results in a prolonged analgesia. FIGURE 2 presents this data.

Table 3

5 Effects of epidurally administered alfentanil (400 µg) on the nociceptive threshold and the CO₂ response function in the dog when given in saline or 2.0, 20% 2-hydroxypropyl- β -cyclodextrin.

	<u>Analgesia (1)</u>		<u>Respiratory function (2)</u>
	<u>Peak MPE</u>	<u>T1/2</u>	<u>(% decrease in slope)</u>
10			
Saline	87%	60 min	40
20% CDEX	26%	40 min	18
2% CDEX	100%	180 min	19

15 1) Peak effect expressed as %MPE; T1/2 expressed as the time (min) required for the effect to decline to approximately 50% of the maximum effect observed after the epidural injection of alfentanil (400 µg). (2) values indicate the maximum percent reduction in the slope of the rate x tidal volume (Ve) response vs. CO₂ measured using the rebreathing techniques.

4. Localization and Redistribution

20 a. Intrathecal injection - rats: Following the intrathecal injection of several opioids, the concentrations of the drug in spinal cord, forebrain and plasma were assessed. As indicated in Table 4, the concentrations of drug in forebrain (indicating the degree of supraspinal redistribution via the vasculature) was significantly reduced after the administration of the CDEX opioid combination in contrast to the concentrations observed when the opioids 25 were administered in saline.

Table 4

Concentrations of alfentanil in brain and plasma following intrathecal injection in the rat.

	<u>Injectate</u>	<u>Time of Measurement</u>	<u>Plasma (ng/ml)</u>	<u>Forebrain (ng/ml)</u>
5	Morphine/saline	5 min	53.7	411.
	Morphine/20% CDEX	5 min	18.1	140.
10	Lofentanil/saline	5 min	1.78	0.96
	Lofentanil/20% CDEX	5 min	0.41	0.0
15	Alfentanil/saline	5 min	146.	75.1
		45 min	10.4	4.1
	Alfentanil/20% CDEX	5 min	135.	81.6
		45 min	10.7	0.0

Each value presents the mean of 4-5 rats.

15 b. Effects of CDEX on alfentanil redistribution in dogs. In dogs prepared with epidural catheters as described above, the injection of 400 μ g of alfentanil in saline resulted in rapid increase to peak plasma drug concentrations. As shown in Table 5, the peak plasma concentrations and total body clearance of alfentanil measured with the coadministration of 400 μ g 20 alfentanil and 20%, and to a lesser extent 2%, CDEX were markedly reduced. The apparent volume of epidural space (Va) was increased by CDEX. Taken together, these results show that CDEX retarded the rate of redistribution of alfentanil from the epidural space to the systemic circulation.

-19-

Table 5

Pharmacokinetic parameters in a 3-exponential model measured in lumbar CSF after the epidural administration of alfentanil (400 μ g).

	5	Saline (N=5)	2% CDEX (N=1) (a)	20% CDEX (N=1) (a)
T1/2abs		1.57	7.2 (3.4)	30.7 (2.2)
T1/2 a		7.9	7.4 (5.8)	32.3 (7.1)
T1/2 b		116.9	324. (31.4)	2179. (152)
C max		1286.	2259. (1119)	257. (2535)
T max		4.66	10.7 (7.1)	----*

10 T1/2abs: halftime of absorption (min); T1/2 a: redistribution; T1/2 b: elimination half life; Cmax: maximum predicted concentration; T max: time (min) to Cmax. *: could not be calculated for 20% CDEX. (a): value indicates results of a single animal. Values in parentheses represents the value observed in that animal without CDEX.

5. Ex Vivo Meningeal Diffusion

15 a. Effects of CDEX on rates of diffusion of opioids from epidural to intrathecal compartments; meningeal permeability studies (ex vivo). A diffusion cell was used to measure meningeal permeability of opioids and other drugs. Live samples of the total spinal meninges (including dura, pia and arachnoid) were dissected from freshly sacrificed Macaque nemestrina monkeys; 20 the tissue was installed in a temperature-controlled two-well diffusion cell and kept viable by constant exposure to mechanically stirred artificial CSF (both surfaces at 37°C continuously saturated with O₂/CO₂). One well (10 ml) of the diffusion cell (A) is employed for addition of 5 ml aliquots of drug in either CSF or along with various concentrations of CDEX in CSF and simultaneous with the 25 addition of solution to well (A), an equal volume of oxygenated CSF is placed in the other well (B). Thereafter, minimal volumes (0.2-0.4 ml) of solution in well (B) are collected for assay at regular intervals for up to 2-24 hours. As volumes are withdrawn from (B), an equal volume is immediately added to maintain the original measured volume. Samples are subjected to assay by HPLC, GC-MS or 30 radiometric methods to measure the concentrations of drug and CDEX that has diffused through the meninges. The slope of the regression line of drug concentrations in (B) vs. time is the flux from which meningeal permeability of that drug is calculated directly.

As an example of flux measurement, the movements of alfentanil and 35 sufentanil have been examined alone (in CSF) and in CSF-CDEX at CDEX concentrations of 2% or 20%. Results show that the rate of diffusion of these

-20-



agents is highly modified by the presence of CDEX. The *ex vivo* model also demonstrates the differential effect of CDEX on different drugs. Thus, the degree of reduction in meningeal flux, after complexation with CDEX, is alfentanil >> sufentanil (FIGURE 3). In 20% CDEX, there is a 10- and 100-fold 5 reduction for sufentanil and alfentanil, respectively. These CDEX modulations in meningeal flux of opioids shown and the relative changes in flux for the two compounds mirror those augmentations in analgesia described in the *in vivo* intrathecal injection model. The extent of the modulation of meningeal transfer for these model drugs through the meninges and to the spinal cord can be adjusted 10 to reach optimal rates of epidural drug delivery to the spinal cord by employing different (optimal) concentrations (and/or molar ratios) of CDEX in combination with the drug administered. Results with the *ex vivo* meningeal model indicate that equivalent variations of CDEX concentrations in CDEX solutions (e.g., 20 vs. 2 vs. 0.2% CDEX, etc.) have different modulatory effects on drugs. As an 15 example, combinations of alfentanil in 20% CDEX produce a 50- to 100-fold reduction in meningeal flux (as compared to alfentanil dissolved in CSF) while 2% CDEX reduces the rate by only 20-fold. This concentration dependency is probably a function of the molar ratio of the free drug to the unoccupied CDEX occupancy sites.

20 While the present invention has been described in conjunction with preferred embodiments, one of ordinary skill after reading the foregoing specification will be able to effect various changes, substitutions of equivalents, and alterations of the subject matter set forth herein. It is therefore intended that the protection granted by Letters Patent hereon be limited only by the definitions contained in 25 the appended claims and equivalents thereof.

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A method of delivering a drug to a patient, comprising administering said drug to the neuraxis of said patient in the form of a complex between said drug and a cyclodextrin, wherein said cyclodextrin comprises at least one substituent selected from the group consisting of $-\text{OCH}_3$, $-\text{ROH}$, $-\text{RSO}_3\text{H}$, $-\text{CO}_2\text{R}$,
5 $-\text{NHR}$, $-\text{NR}_2$, $-\text{NROH}$, and $-\text{SiR}_3$, wherein each R is independently selected from C_{1-10} alkyl groups that may be linear, branched, or cyclic.
2. The method according to Claim 1, wherein said inclusion complex is administered to said patient intraventricularly, intrathecally, or epidurally.
3. The method according to Claim 1, wherein said drug is an analgesic.
4. The method of Claim 3, wherein said analgesic is an opioid.
5. The method of Claim 4, wherein said opioid is selected from the group consisting of alfentanil, lofentanil, sufentanil, fentanyl, and morphine.
6. The method according to Claim 1, wherein said drug is an antineoplastic or cancer chemotherapeutic agent.
7. The method according to Claim 7, wherein said agent is methotrexate or busulfan.
8. The method of Claim 1, wherein said drug is a cerebral ischemia protectant.
9. The method according to Claim 1, wherein said cyclodextrin is a hydroxy (C_{1-6} alkyl)- β -cyclodextrin.
10. The method according to Claim 1, wherein said cyclodextrin comprises six to eight glucose molecules.
11. The method according to Claim 1, wherein said complex has a molar ratio of cyclodextrin:drug of about 1:10 to about 1:10,000.

12. The method according to Claim 1, wherein said patient is a human.
13. A composition for delivery of a drug to the neuraxis of a patient, comprising a drug active in the neuraxis of a patient complexed with a cyclodextrin, wherein said cyclodextrin comprises at least one substituent selected from the group consisting of $-\text{OCH}_3$, $-\text{ROH}$, $-\text{RSO}_3\text{H}$, $-\text{CO}_2\text{R}$, $-\text{NHR}$, $-\text{NR}_2$, $-\text{NROH}$, and $-\text{SiR}_3$, wherein each R is independently selected from C_{1-10} alkyl groups that may be linear, branched, or cyclic.
5
14. The composition of Claim 13, wherein said drug is an analgesic.
15. The composition of Claim 14, wherein said analgesic is an opioid.
16. The composition according to Claim 15, wherein said opioid is selected from the group consisting of alfentanil, lofentanil, sufentanil, fentanyl, and morphine.
17. The composition according to Claim 13, wherein said drug is an antineoplastic agent.
18. The method according to Claim 17, wherein said agent is methotrexate or busulfan.
19. The method according to Claim 13, wherein said drug is a cerebral ischemia protectant.
20. The composition according to Claim 13, wherein said cyclodextrin is a hydroxy (C_{1-6} alkyl)- β -cyclodextrin.
21. The composition according to Claim 13, wherein said cyclodextrin comprises six to eight glucose molecules.
22. The composition according to Claim 13, wherein said complex has a molar ratio of cyclodextrin:drug of about 1:10 to about 1:10,000.

**FIG. 1A.****FIG. 1B.**




FIG.2A.




FIG.2B.




FIG.2C.




FIG.2D.




FIG.2E.




FIG.2F.

5/5




FIG. 3A.




FIG. 3B.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 91/05360

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all):

According to International Patent Classification (IPC) or to both National Classification and IPC
Int. Cl. 5 A 61 K 47/48

II. FIELDS SEARCHED

Minimum Documentation Searched?

Classification System	Classification Symbols
Int.C1.5	A 61 K

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ^a	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	<p>Drug Design and Delivery, volume 2, 1988, Harwood Academic Publishers GmbH (London, GB) W.R. Anderson et al.: "Brain-enhanced delivery of testosterone using a chemical delivery system complexed with 2-hydroxypropyl-beta-cyclodextrin", pages 287-298, see page 287, abstract; page 296, paragraph 2</p> <p>---</p>	1-5, 9-16, 20-22
Y	<p>Anesthesiology, volume 64, 1986 (Philadelphia, PA, US) T.L. Yaksh et al.: "Studies of the pharmacology and pathology of intrathecally administered 4-anilinopiperidine analogues and morphine in the rat and cat", pages 54-66, see page 54, abstract (cited in the application)</p> <p>---</p>	1-7, 9-18, 20-22

° Special categories of cited documents :¹⁰

"A" document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

•17 document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

P document published prior to the invention later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search 22-10-1991	Date of Mailing of this International Search Report 23. 01. 92
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer  MISS T. MORTENSEN

III. DOCUMENTS CONSIDERED TO BE RELEVANT		(CONTINUED FROM THE SECOND SHEET)
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	Journal of Chromatography, volume 205, 1981, Elsevier Scientific Publishing Company (Amsterdam, NL) K. Koizumi et al.: "Determination of barbiturates in mouse tissues by high-performance liquid chromatography", pages 401-412, see page 401, summary; page 411, paragraph 2 ---	1-22
X	Life Sciences, volume 43, 1988 Pergamon Press (Elmsford, N.Y., US) J. Pitha et al.: "Drug solubilizers to aid pharmacologists: amorphous cyclodextrin derivatives", pages 493-502, see page 493, summary; page 499, last paragraph; page 501, first paragraph (cited in the application) ---	1,2,9- 13,20- 22
Y	(cited in the application) ---	1,2,8- 13,19- 22
A	International Journal of Pharmaceutics, volume 29, 1986, Elsevier Science Publishers B.V. (Amsterdam, NL) J. Pitha et al.: "Hydroxypropyl-beta-cyclodextrin: preparation and characterization; effects on solubility of drugs", pages 73-82, see page 73, summary; page 80, table 1 (cited in the application) ---	1-22
Y	EP,A,0327766 (UNIVERSITY OF FLORIDA) 16 August 1989, see page 11, line 51 - page 12, line 20; page 14, line 34 - page 16, line 44 ---	1-7,9- 18,20- 22
Y	DE,A,3315356 (ONO PHARMACEUTICAL CO. LTD) 17 November 1983, see claims 1,2 ---	1,2,8- 13,19- 22
P,X	Life Sciences, volume 48, no. 7, 10 January 1991, Pergamon Press (Elmsford, N.Y., US) T.L. Yaksh et al.: "The utility of 2-hydroxypropyl-beta-cyclodextrin as a vehicle for the intracerebral and intrathecal administration of drugs", pages 623-633, see page 623, summary ---	1-5,9- 16,20- 22

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P,X	<p>Society for Neuroscience, volume 16, Abstracts of the 20th Annual Meeting of the Society for Neuroscience, 28 October - 2 November 1990 in St. Louis, Missouri (US) J. Jang et al.: "Effect of beta-cyclodextrin on analgesia produced by intrathecally administered opioids", page 211, see abstract 95.8</p> <p>-----</p>	1-5, 9- 16, 20- 22

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-12 are directed to a method of treatment of the human/animal body (PCT Rule 39.1(iv)) the search has been carried out and based on the alleged effects of the compound/composition.
2. Claim numbers because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically.
3. Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple Inventions in this International application as follows:

1. As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application
2. As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims:
3. No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9105360
SA 50528

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 30/12/91. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A- 0327766	16-08-89	US-A-	5002935	26-03-91
		AU-A-	2733988	06-07-89
		AU-A-	3176289	27-07-89
		JP-A-	1294663	28-11-89
		US-A-	4983586	08-01-91
		US-A-	5017566	21-05-91
		US-A-	5024998	18-06-91
<hr/>				
DE-A- 3315356	17-11-83	JP-C-	1592621	14-12-90
		JP-B-	2013644	04-04-90
		JP-A-	58192821	10-11-83
		JP-B-	1029168	08-06-89
		JP-A-	59073522	25-04-84
		BE-A-	896621	03-11-83
		US-A-	4499085	12-02-85
<hr/>				